Press Releases FluoGuide A/S

Equities

FLUO

DK0061123312

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 28/06/2024 BST			5-day change	1st Jan Change
41.75 ^SEK	-5.11%		-7.12%	-31.78%

05-30	FluoGuide A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-27	FluoGuide Picks Laser System for FG001 Photothermal Therapy Treatment	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

FluoGuide has completed a directed share issue to existing and new investors raising proceeds of SEK 60 million	06-18	AQ
FluoGuide intends to carry out a directed share issue of approximately SEK 60 million	06-18	AQ
Fluoguide Q1 2024 - Preparing for next steps	05-30	AQ
FluoGuide A/S publishes interim report for the period January – March 2024	05-30	AQ
FluoGuide selects laser system for photothermal cancer therapy with FG001	05-27	AQ
Minutes from Annual General Meeting in FluoGuide A/S	03-20	AQ
Chief Financial Officer (CFO) Ole Larsen buys shares	03-13	AQ
FluoGuide enters collaboration within robot assisted head and neck cancer surgery with Intuitive Surgical, a world leading robotic-assisted surgery company	03-12	AQ
Notice of Annual General Meeting in FluoGuide A/S	03-01	AQ
Fluoguide Q4 2023 - Bright prospects	02-28	AQ
FluoGuide A/S publishes year-end and annual report for the fiscal year 2023	02-28	AQ
FluoGuide A/S issues warrants to CFO	02-23	AQ
FluoGuide provides strategic update and outlines development plans towards commercialization of FG001	01-08	AQ
FluoGuide raises SEK 12 million through exercise of warrants	12-11	AQ
Chief Development Officer (CDO) Grethe Nørskov Rasmussen sells shares	12-09	AQ
FluoGuide raises SEK 12 million through exercise of warrants	12-08	AQ
Fluoguide Q3 2023 - Spoilt for choice	11-29	AQ
FluoGuide A/S publishes interim report for the period January – September 2023	11-29	AQ
FluoGuide announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer	11-13	AQ
FluoGuide confirms positive topline results from phase lla trial of FG001 in head & neck cancer at International Academy of Oral Oncology conference	11-06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases FluoGuide A/S

Equities

FLUO

DK0061123312

Press Releases

Filters